Real-World Performance of the Afirma Genomic Sequencing Classifier (GSC)—A Meta-analysis
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgac688 ↗Kurz gefasst
Metaanalyse in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Christian E Nasr und 16 weiteren Autor:innen. Beteiligte Einrichtung: University of Arizona College of Medicine Phoenix, Phoenix, AZ 85004, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyroid Nodule. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Context
The Afirma® GSC aids in risk stratifying indeterminate thyroid nodule cytology (ITN). The 2018 GSC validation study (VS) reported a sensitivity (SN) of 91%, specificity (SP) of 68%, positive predictive value (PPV) of 47%, and negative predictive value (NPV) of 96%. Since then, 13 independent real-world (RW) postvalidation studies have been published.
Objective
This study's objective is to compare the RW GSC performance to the VS metrics.
Methods
Rules and assumptions applying to this analysis include: (1) At least 1 patient with molecular benign results must have surgery for that study to be included in SN, SP, and NPV analyses. (2) Molecular benign results without surgical histology are considered true negatives (TN) (as are molecular benign results with benign surgical histology). (3) Unoperated patients with suspicious results are either excluded from analysis (observed PPV [oPPV] and observed SP [oSP]) or assumed histology negatives (false positives; conservative PPV [cPPV] and conservative SP [cSP]) 4. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features is considered malignant.
Results
In RW studies, the GSC demonstrates a SN, oSP, oPPV, and NPV of 97%, 88%, 65%, 99% respectively, and conservative RW performance showed cSP of 80% and cPPV of 49%, all significantly higher than the VS except for SN and cPPV. There was also a higher benign call rate (BCR) of 67% in RW studies compared to 54% in the VS (P < 0.05).
Conclusion
RW data for the Afirma GSC demonstrates significantly better oSP and oPPV performance than the VS, indicating an increased yield of cancers for resected GSC suspicious nodules. The higher BCR likely increases the overall rate of clinical observation in lieu of surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Arizona College of Medicine Phoenix, Phoenix, AZ 85004, USA.
- Centro EndocrinologiaOggi, 00199 Roma, Italy.
- Endocrine Care Center at University of Washington Medical Center, Seattle, WA 98105, USA.
- Memorial Healthcare System, Hollywood, FL 33021, USA.
- Endocrine Center, UCLA, Los Angeles, CA 90095, USA.
- Division of Endocrinology, Umass Chan Medical School, Baystate, Springfield, MA 01199, USA.
ORCID-Profile: Christian E Nasr, Joshua P Klopper
Zitieren
APA
Nasr, C. E., Andrioli, M., Endo, M., Harrell, R. M., Livhits, M. J., Osakwe, I., Polavarapu, P., Siperstein, A., Wei, S., Zheng, X., Jiang, R., Hao, Y., Huang, J. I. N., Klopper, J. P., Kloos, R. T., Kennedy, G., & Angell, T. E. (2023). Real-World Performance of the Afirma Genomic Sequencing Classifier (GSC)—A Meta-analysis. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac688
Vancouver
Nasr CE, Andrioli M, Endo M, Harrell RM, Livhits MJ, Osakwe I, et al. Real-World Performance of the Afirma Genomic Sequencing Classifier (GSC)—A Meta-analysis. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgac688
BibTeX
@article{Nasr2023,
author = {Nasr, Christian E and Andrioli, Massimiliano and Endo, Mayumi and Harrell, R Mack and Livhits, Masha J and Osakwe, Ibitoro and Polavarapu, Preethi and Siperstein, Allan and Wei, Shuanzeng and Zheng, Xingyu and Jiang, Ruochen and Hao, Yangyang and Huang, J I Ng and Klopper, Joshua P and Kloos, Richard T and Kennedy, Giulia and Angell, Trevor E},
title = {Real-World Performance of the Afirma Genomic Sequencing Classifier (GSC)—A Meta-analysis},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgac688}
}
EUVIMED